Akers Biosciences' stock soars 29% on merger deal

The combined company will be based in Baltimore and focus on developing treatments for autoimmune and age-related diseases.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news